Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDCI-01 in Pulmonary Arterial Hypertension Phase II Trial
CTR20221194Phase 2Completed
- Sponsor
- Chongqing Dikang Erle Pharmaceutical
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DDCI-01 in pulmonary arterial hypertension (PAH), sponsored by Chongqing Dikang Erle Pharmaceutical. Started May 2022; status: completed.
02
Drugs
DDCI-01
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on CTR20221194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221194.